Proactive Investors - Run By Investors For Investors

Arcturus Therapeutics stock rockets higher amid expansion of Ultragenyx collaboration

The companies plan to discover and develop mRNA, DNA and small interfering RNA therapeutics to target a slate of rare diseases
Arcturus scientist in a lab
The partnership will pay Arcturus for major milestones reached in the development process

Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) shares surged after the messenger RNA medicine company announced Wednesday the continuation of its collaboration with Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

The companies plan to discover and develop mRNA, DNA and small interfering RNA therapeutics to target a slate of rare diseases.

Arcturus shares jumped nearly 42% to $8.19. Shares of Ultragenyx, a large-cap pharmaceutical company, ticked up 0.6% to $62.70.

READ: Melinta stock doubles on FDA approval of a supplemental new drug application for BAXDELA to treat pneumonia

The partnership will pay Arcturus for major milestones reached in the development process. The two companies have been working together since October 2015.

The first such treatment is designed to treat Glycogen Storage Disease Type III, a hereditary disorder that impairs the body’s ability to break down carbohydrates.

“The expansion of the collaboration with Ultragenyx underscores the partnership’s early successes and ongoing commitment,” CEO Joseph Payne said. “Our expertise in the discovery, early development and manufacturing of RNA medicines aligns well with Ultragenyx’s proven clinical development and commercial experience in rare diseases.”

Arcturus Therapeutics is an RNA medicines company based in San Diego, California. Itstreatment pipeline includes therapies for Ornithine Transcarbamylase Deficiency, Cystic Fibrosis, Glycogen Storage Disease Type 3, Hepatitis B, and non-alcoholic steatohepatitis.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full ARCT profile View Profile

Related Articles

woman touching her skin
May 21 2019
Here we take a closer look at Integumen PLC (LON:SKIN), which has developed and digitised an artificial skin
An instrument made by Pressure BioSciences
June 26 2019
The company’s high-pressure technologies can help drug makers produce protein-based therapeutics, a market expected to touch $240 billion by 2023
Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use